Cancer peptide database for tumor-associated antigens | LifeTein Peptide Blog

FDA-approved for promoting weight regain following involuntary weight loss due to major surgery. Oxandrolone accelerates lean mass recovery and improves nitrogen balance during the recovery period. Extensively studied in severe burn patients, where oxandrolone reduces protein catabolism, accelerates wound healing, shortens hospital stays, and improves long-term lean body mass outcomes. Widely used in major burn centers. Effective for reversing muscle wasting and weight loss in patients with HIV/AIDS. Increases lean body mass and improves functional capacity in wasting syndrome. FDA-approved indication for weight recovery after chronic infections that result in significant involuntary weight loss. Counteracts catabolic effects of prolonged corticosteroid therapy by enhancing nitrogen retention and protein synthesis, helping preserve lean mass during necessary glucocorticoid treatment. FDA-approved for relief of bone pain accompanying osteoporosis. Increases bone mineral density and reduces pain scores in osteoporotic patients, particularly postmenopausal women. Used as adjunctive therapy with growth hormone in girls with Turner syndrome to improve final adult height. Clinical trials show additive benefit when combined with GH therapy. Promotes nitrogen retention and anti-catabolic effects during energy restriction, preserving lean tissue while facilitating fat loss. Commonly used during cutting phases. Increases muscular strength through enhanced protein synthesis and creatine phosphate regeneration, without the water retention associated with aromatizing compounds. Clinical studies have demonstrated selective reduction in abdominal and visceral adipose tissue with oxandrolone treatment, independent of total caloric intake changes.

Join others researching Ecdysterone — share findings, ask questions, and learn from real experiences Ecdysterone (20-Hydroxyecdysone) is a naturally occurring phytoecdysteroid -- a class of steroid hormones that regulate molting and metamorphosis in insects and crustaceans. Despite its name and steroidal structure, ecdysterone does not interact with the androgen receptor and operates through an entirely different mechanism than anabolic-androgenic steroids. It is found in meaningful concentrations in common foods such as spinach (Spinacia oleracea), quinoa (Chenopodium quinoa), and various other plants. Ecdysterone gained significant attention in the strength and performance community following a 2019 study from Freie Universitat Berlin, which demonstrated that trained individuals supplementing with ecdysterone experienced significantly greater muscle mass gains compared to placebo over a 10-week resistance training program. The effect sizes were large enough that the study authors themselves recommended the World Anti-Doping Agency (WADA) consider adding ecdysterone to the prohibited substances list. Unlike traditional anabolic agents, ecdysterone does not cause hormonal suppression, does not require post-cycle therapy, and carries an exceptionally mild side effect profile. Its mechanism appears to involve signaling through estrogen receptor beta (ERbeta), which activates anabolic pathways in skeletal muscle without the androgenic, estrogenic, or hepatotoxic effects associated with traditional performance-enhancing compounds. An injectable form has gained popularity among advanced users seeking higher bioavailability, as oral ecdysterone suffers from significant first-pass metabolism. Ecdysterone's anabolic mechanism is fundamentally distinct from that of anabolic-androgenic steroids. Rather than binding to the androgen receptor, ecdysterone exerts its effects primarily through estrogen receptor beta (ERbeta) signaling. ERbeta is expressed in skeletal muscle tissue, and its activation triggers downstream anabolic signaling cascades including the PI3K/Akt pathway, which promotes muscle protein synthesis and inhibits protein degradation. This pathway converges on mTOR (mechanistic target of rapamycin), a master regulator of muscle hypertrophy, leading to increased translation of muscle-specific proteins. Importantly, ecdysterone does not activate estrogen receptor alpha (ERalpha), which is responsible for the feminizing effects of estrogens, nor does it bind to the androgen receptor, glucocorticoid receptor, or mineralocorticoid receptor. This selectivity explains why ecdysterone does not produce the hormonal side effects associated with anabolic steroids -- there is no testosterone suppression, no testicular atrophy, no gynecomastia, no liver toxicity, and no virilization in women. Additional proposed mechanisms include enhanced nitrogen retention in muscle tissue, improved calcium handling in muscle fibers leading to better contractile efficiency, and mild anti-inflammatory effects that may support recovery from exercise-induced muscle damage. Some in vitro studies also suggest ecdysterone may increase satellite cell proliferation, which could contribute to long-term muscle growth capacity.